Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
New research confirms that many of the challenges sponsors face managing clinical trials stem from the disparate nature of processes and systems.
Much has been written about opportunities for improving the drug development process. Although there are many areas ripe for process improvements, let’s focus on the following five.
Many parents can tell a story about the lengths they’ve gone to help their children when no doctor could provide an answer. But there’s one story that stands out to me above the rest because it really drives home the vital need for data sharing, digital collaboration, and the establishment of a connected health ecosystem in the life sciences industry.
Often when we think about inefficiencies in the clinical trial process, we focus on the role of the sponsor or CRO, a particular aspect of the value chain, or new technologies that promote data sharing and faster decision making. While these are critical aspects that drive day-to-day operations, there is another aspect of the value chain that we may be neglecting: the patient side.
With wearables, we now have the means to innovate the “where” and the “how” of patient data capture, creating a 24-hour digital map of physical behaviors.
One of the most vexing and common problems HR professionals face is acquiring and training talent for specific skilled positions, only to see that talent, and the time and money invested in them, walk out the door too soon.
The very nature of many scientific processes creates habitual behaviors. Often these habits are effectively passed from senior lab generations to younger ones. Old habits can be hard to break, especially in a time-pressured lab environment.
Although the history of drug development contains many stories of serendipitous discovery, critical advances often emerge by setting out to address specific challenges. Today, many challenges associated with older drugs are being solved with new delivery technologies.
Any biotech or life sciences company in Boston — early-stage or mature — is no stranger to Kendall Square’s lab space squeeze. As the top-performing lab market in the U.S., Kendall Square is especially sought after by life sciences companies — ranging from emerging startups to Big Pharma.
Oncology has always been the front runner in personalized medicine, so this is where targeted therapies and diagnostics have, for the most part, been focused. However, there is new activity outside this area where biomarker and targeted approaches are proving successful.
Daniel Skovronsky, M.D., Ph.D., is the SVP of clinical and product development at Eli Lilly and Company. But prior to taking on this role, he held the title of CEO of Avid Radiopharmaceuticals — a company he founded in Philadelphia while still a graduate student at the University of Pennsylvania. This article explores some of the differences between this executives past and present roles, and is a good prequel to the upcoming article that explores how he went about building a $300 million company.
When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”
Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.
Today we stand on the precipice overlooking a new frontier — the century of biology, and businesses of all kinds need to be prepared to not only embrace what is coming, but have a strategy for how to leverage biology for the betterment of their businesses and the good of the planet.
Life Science Leader Chief Editor Rob Wright is cochairing the 2018 BIO educational program planning committee. In this blog he talks about why this was the earliest the planning committee has ever met and what you can do to submit interesting and novel session proposals that will get the attention of the committee.